AUTHOREA
Log in Sign Up Browse Preprints
LOG IN SIGN UP
C.J. Jiménez-Becerra
C.J. Jiménez-Becerra
Guadalajara, Jal
Member of: Centro Universitario de Ciencias de la Salud Centro Universitario de Ciencias de la Salud (CUCS) Departamento de Biología Molecular de CUCS. Cuerpo de instructores de la Academia de Bioquímica

Public Documents 1
Clopidogrel therapy in ACS: What's the role of CYP2C19* 2 polymorphism?
K. O. Hernández-Muñoz
C.J. Jiménez-Becerra

K.O. Hernández-Muñoz

and 5 more

December 03, 2020
gOver 16 million people die every year by cardiovascular diseases, acute coronary syndrome is part of the spectrum.\cite{2000-20162018}A widely used approach is platelet aggregation inhibition by clopidogrel, drastically diminishing mortality but it doesn't works the same for everyone, a CYP2C19* 2 polymorphism could led your patient to a shorter life. How common is this? What about intermediate metabolizers? Do we need to think in alternative treatment? what is the importance of CYP2C19* 2 polymorphism versus other polymorphism? this and other topics would be addressed in this review.
Authorea
  • Home
  • About
  • Product
  • Preprints
  • Pricing
  • Blog
  • Twitter
  • Help
  • Terms of Use
  • Privacy Policy